Hospira infusion pump recall gets class I notice
This article was originally published in Clinica
The US FDA has given the recall of Hospira’s Symbiq infusion pump a class I classification. Hospira notified customers on 9 April that the product could fail to detect the delivery of air to a patient at the end of an infusion; this could potentially cause serious injury or death. On 11 June, the company updated its communications to customers, saying that users do not have to remove or stop using the Symbiq pump. The device is used for the delivery of fluids including solutions, drugs, nutrition, electrolytes, blood and blood products via parenteral, enteral, intravenous, intra-arterial, subcutaneous, epidural or irrigation routes of administration. Hospira said that “the root cause for the failure to detect air in line continues to be investigated”.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals